Featured Research

from universities, journals, and other organizations

Breast cancer: New treatment avenue identified

Date:
May 17, 2011
Source:
Centre hospitalier de l'Université de Montréal
Summary:
Researchers in Canada and Australia have identified a new avenue for treating breast cancer.

Researchers at the CHUM Research Centre (CRCHUM) and the Peter MacCallum Cancer Centre in Australia have identified a new avenue for treating breast cancer.

Related Articles


In 20 to 30% of breast cancer patients, the over-expression of a particular protein (human epidermal growth factor-2) is the main cause of the proliferation of cancer cells. Over the past few years Herceptin® (trastuzumab) has become the standard treatment for this kind of cancer. While it is known that it blocks the activity of this protein, its exact mechanism of action has remained a mystery.

Professor John Stagg, a CRCHUM researcher, Professor Mark J. Smyth, with the Peter MacCallum Cancer Centre in Australia, and their colleagues have discovered that in addition to blocking cell proliferation, Herceptin also stimulates the production of interferons, which in turn activate immune cells called lymphocytes.

This study further supports the view that the presence of lymphocytes in tumours enhances treatment success. In addition to revealing the precise workings of Herceptin, this study also showed that combining Herceptin with a therapy that stimulates lymphocytes greatly increases its efficacy in animals.

"These findings open another avenue for breast cancer treatment for nearly a third of all women who are affected," notes Professor Stagg, who is also affiliated with the Faculty of Pharmacy at the University of Montreal and with the Institut du Cancer de Montréal. Clinical trials could get underway in the near future and pave the way for more targeted therapies.

This study was conducted in collaboration with the Peter MacCallum Cancer Centre, East Melbourne, Australia; Jules Bordet Institute, Brussels, Belgium; University of Melbourne, Australia; and Juntendo University, Tokyo, Japan;

The study was funded by the National Health and Medical Research Council of Australia, the Susan Komen Breast Cancer Foundation and the Victoria Breast Cancer Research Consortium (Australia).


Story Source:

The above story is based on materials provided by Centre hospitalier de l'Université de Montréal. Note: Materials may be edited for content and length.


Journal Reference:

  1. J. Stagg, S. Loi, U. Divisekera, S. F. Ngiow, H. Duret, H. Yagita, M. W. Teng, M. J. Smyth. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proceedings of the National Academy of Sciences, 2011; 108 (17): 7142 DOI: 10.1073/pnas.1016569108

Cite This Page:

Centre hospitalier de l'Université de Montréal. "Breast cancer: New treatment avenue identified." ScienceDaily. ScienceDaily, 17 May 2011. <www.sciencedaily.com/releases/2011/05/110517073940.htm>.
Centre hospitalier de l'Université de Montréal. (2011, May 17). Breast cancer: New treatment avenue identified. ScienceDaily. Retrieved November 28, 2014 from www.sciencedaily.com/releases/2011/05/110517073940.htm
Centre hospitalier de l'Université de Montréal. "Breast cancer: New treatment avenue identified." ScienceDaily. www.sciencedaily.com/releases/2011/05/110517073940.htm (accessed November 28, 2014).

Share This


More From ScienceDaily



More Health & Medicine News

Friday, November 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Ebola Leaves Orphans Alone in Sierra Leone

Ebola Leaves Orphans Alone in Sierra Leone

AFP (Nov. 27, 2014) — The Ebola epidemic sweeping Sierra Leone is having a profound effect on the country's children, many of whom have been left without any family members to support them. Duration: 01:02 Video provided by AFP
Powered by NewsLook.com
Experimental Ebola Vaccine Shows Promise In Human Trial

Experimental Ebola Vaccine Shows Promise In Human Trial

Newsy (Nov. 27, 2014) — A recent test of a prototype Ebola vaccine generated an immune response to the disease in subjects. Video provided by Newsy
Powered by NewsLook.com
Pet Dogs to Be Used in Anti-Ageing Trial

Pet Dogs to Be Used in Anti-Ageing Trial

Reuters - Innovations Video Online (Nov. 26, 2014) — Researchers in the United States are preparing to discover whether a drug commonly used in human organ transplants can extend the lifespan and health quality of pet dogs. Video provided by Reuters
Powered by NewsLook.com
Today's Prostheses Are More Capable Than Ever

Today's Prostheses Are More Capable Than Ever

Newsy (Nov. 26, 2014) — Advances in prosthetics are making replacement body parts stronger and more lifelike than they’ve ever been. Video provided by Newsy
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins